Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Natco Pharma intends to defend the matter accordingly
FDA has concluded that this inspection is 'closed'
Subscribe To Our Newsletter & Stay Updated
